E

    Envoy Medical Inc. (COCH)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.73
    +0.04 (+5.64%)

    Market Cap: $53.27M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    27%(3/11)
    Avg Surprise
    -20.45%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.07
    Range$-0.07 - $-0.07
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.06+14.3%
    60d ago$-0.06+14.3%
    30d ago$-0.06+14.3%
    7d ago$-0.07+0.0%
    Current$-0.07
    Revenue Consensus
    $80000
    Range$60000 - $100000
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.01
    Range$-0.02 - $0.01
    2 analysts
    Revenue Consensus
    $30000
    Range$-20000 - $80000
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.01---
    Sep 26EST
    		-$-0.07---
    Jun 26
    		$-0.07$-0.09+22.22%Beat+78.1%
    Mar 26
    		$-0.08$-0.14+42.86%Beat+72.4%
    Dec 25
    		$-0.27$-0.29+7.79%Beat+41.9%
    Sep 25
    		$-0.35$-0.29-20.69%Miss+5.4%
    Jun 25
    		$-0.32$-0.29-10.34%Miss-18.5%
    Mar 25
    		$-0.29$-0.20-45.00%Miss+9.4%
    Dec 24
    		$-0.46$-0.31-48.39%Miss-17.9%
    Sep 24
    		$-0.37$-0.27-37.04%Miss-395.5%
    Jun 24
    		$-0.27$-0.25-8.00%Miss-254.3%
    Mar 24
    		$-0.32$-0.26-23.08%Miss-700.0%
    Dec 23
    		$-0.39$-0.19-105.26%Miss-931.7%
    Sep 23
    		$0.13N/AN/ABeat+13.8%
    Jun 23
    		$-0.08N/AN/ABeat-227.0%
    Mar 23
    		$-0.04N/AN/ABeat-117.4%
    Dec 22
    		$-0.04N/AN/ABeat+58.0%
    Sep 22
    		$0.11N/AN/ABeat+10.0%
    Jun 22
    		$0.06N/AN/ABeat+500.0%
    Mar 22
    		$0.23N/AN/ABeat+866.7%
    Dec 21
    		$-0.09N/AN/ABeat-
    Sep 21
    		$0.10N/AN/ABeat-
    Jun 21
    		$0.01N/AN/ABeat-
    Mar 21
    		$-0.03$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.95EV/EBITDA-1.35x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-10920.00%
    ROE0.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.73xQuick Ratio1.61x
    Trading Statistics
    Beta1.89Avg Volume106.92K
    52-Week High$1.8952-Week Low$0.36

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.74
    SMA 20$0.73
    SMA 50$0.71
    SMA 200$0.70
    EMA 10$0.73
    EMA 20$0.73
    EMA 50$0.71
    EMA 200$0.77

    MACD

    Line: 0.01Signal: 0.01Hist: -0.00

    ADX

    ADX: 23.0+DI: 16.1-DI: 15.1

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down8.0
    PSAR$0.81

    Bollinger Bands

    Upper Band$0.80
    Lower Band$0.66
    %B Position1805%(Upper)
    Band Width0.50

    RSI (14-Day)

    Neutral
    51.3

    Momentum Oscillators

    Stoch %K26.0
    Stoch %D36.4
    Williams %R-68.6
    ROC (10d)-0.8%
    Momentum-0.01
    CCI (20d)-35.7
    MFI (14d)37.4

    Volatility Measures

    ATR (14d)$0.04(6.0%)
    StdDev (20d)0.03
    Hist Vol63.8%(High)

    Volume Flow

    VWAP$0.72
    OBV177.6M
    AD Line-36.8M
    CMF (20d)0.115

    Volume Metrics

    Avg Vol (20d)105.5K
    Vol Ratio0.3x(Low)
    VWMA (20d)$0.74

    Pivot Points

    R3$0.80
    R2$0.78
    R1$0.74
    Pivot Point$0.71
    S1$0.67
    S2$0.64
    S3$0.60

    Advanced Oscillators

    TSI5.31
    Ultimate Osc49.4
    KST56.77

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$51,000$39,000$75,000$42,000$78,000$46,000$42,000$56,000$68,000$59,000$95,000$80,000
    Cost of Revenue$278,000$313,000$211,000$203,000$234,000$226,000$157,000$187,000$245,000$153,000$263,000$189,000
    Gross Profit$-227,000$-274,000$-136,000$-161,000$-156,000$-180,000$-115,000$-131,000$-177,000$-94,000$-168,000$-109,000
    Operating Expenses$5.34M$5.68M$6.25M$5.55M$4.91M$4.93M$4.43M$4.84M$4.67M$4.79M$6.55M$3.28M
    R&D$3.13M$3.64M$4.55M$2.70M$2.48M$2.75M$2.47M$2.76M$2.59M$2.36M$3.03M$1.85M
    SG&A$2.03M$1.88M$1.60M$2.44M$2.07M$1.82M$1.44M$1.69M$1.59M$2.10M$3.02M$1.03M
    Operating Income$-5,569,000$-5,959,000$-6,385,000$-5,708,000$-5,070,000$-5,107,000$-4,548,000$-4,972,000$-4,852,000$-4,884,000$-6,723,000$-3,385,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$201,000$471,000$624,000$495,000$384,000$264,000$132,000$36,000$0$0
    Income Before Tax$-5,982,000$-4,351,000$-6,586,000$-6,482,000$-5,690,000$-4,998,000$-4,618,000$-5,960,000$-3,947,000$-6,270,000$-4,986,000$1.56M
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,982,000$-4,351,000$-6,586,000$-6,482,000$-5,690,000$-4,998,000$-4,618,000$-5,960,000$-3,947,000$-6,270,000$-4,986,000$1.56M
    EBITDA$-5,672,000$-4,051,000$-6,276,000$-5,222,000$-4,112,000$-3,700,000$-3,564,000$-5,113,000$-3,336,000$-5,930,000$-4,336,000$1.59M
    EBIT$-5,982,000$-4,351,000$-6,586,000$-6,011,000$-5,066,000$-4,503,000$-4,234,000$-5,696,000$-3,815,000$-6,234,000$-4,986,000$1.56M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about COCH

    News

    Envoy Medical (NASDAQ: COCH) raises cash, advances fully implanted cochlear implant

    Envoy Medical (NASDAQ: COCH) reported its Q2 2026 financial results, including a net loss of $7.3 million and net revenue of $51,000. The company significantly increased its cash position to $19.7 million from $3.7 million at year-end 2025, supported by $30 million in equity and warrant financing. Envoy Medical also made substantial progress on its fully implanted Acclaim cochlear implant, submitting the first module of its PMA application to the FDA and reporting positive 12-month data from clinical trials.

    Stock Titan•8/10/26•
    Somewhat-Bullish

    Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones

    Envoy Medical reported its second quarter 2026 financial results, highlighting significant progress in its corporate initiatives, particularly with its investigational Acclaim® cochlear implant. The company submitted the first module of its modular PMA application to the FDA and announced positive 12-month data from its pivotal clinical trial, showing continued improvement in speech perception. Financially, the company reported a net loss of $7,272 thousand for the quarter and had approximately $19,679 thousand in cash as of June 30, 2026.

    TradingView•8/10/26•
    Bullish

    Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones

    Envoy Medical Inc. reported its second-quarter 2026 financial results, highlighting significant progress towards bringing its fully implanted cochlear implant to market. The company submitted the first module of its modular PMA application to the FDA and announced positive 12-month data from its pivotal clinical trial, showing continued improvement in speech perception. Financially, the company reported a net loss of $7.272 million for the quarter, with cash reserves of approximately $19.679 million as of June 30, 2026.

    TMX Newsfile•8/10/26•
    Bullish

    EXCLUSIVE: Envoy Medical Hits Key Clinical Trial Milestone for Fully Implanted Ear Implant

    Envoy Medical has reached a significant milestone, surpassing the three-month mark for all 56 patients in its pivotal clinical trial for the Acclaim cochlear implant. The company is on track for FDA submission and anticipates achieving six-month and twelve-month visit milestones by late 2026 and April 2027, respectively. The Acclaim implant is designed to address severe to profound sensorineural hearing loss, and recent 12-month results showed substantial improvement in hearing performance among initial participants.

    Sahm•7/22/26•
    Bullish

    Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial

    Envoy Medical Inc. announced that all 56 patients in its pivotal clinical trial for the investigational fully implanted Acclaim® cochlear implant have surpassed the three-month visit milestone. This achievement brings the company closer to submitting its Premarket Approval application to the FDA for the Acclaim CI, an investigational device designed to address severe to profound sensorineural hearing loss. The company anticipates reaching the six-month milestone by late 2026 and the 12-month milestone by April 2027.

    TMX Newsfile•7/21/26•
    Bullish

    Frequently Asked Questions About COCH

    Does COCH pay dividends?
    Envoy Medical Inc. (COCH) does not currently pay a regular dividend.
    What is COCH's market cap?
    Envoy Medical Inc. (COCH) has a market capitalization of $53.27M with a current stock price of $0.73.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In